TARS2 and cholelithiasis: This suggests that bisacodyl may exert a similar effect on gallbladder smooth muscle, potentially promoting bile secretion and reducing gallstone formation.[31] Neostigmine bromide has been identified as a candidate drug for cholelithiasis targeting the LIAS and TARS2 genes.